Latest investigations into retatruptide peptide reveal promising outlook for treating obesity and type 2 diabetes. The molecule, a dual agonist of GLP-1 and GIP, looks to present greater body mass and glycemic control in contrast to existing therapies. Ongoing research efforts are necessary to fully evaluate its safety history and extended effectiv